Edition:
United Kingdom

Vitrolife AB (VITR.ST)

VITR.ST on Stockholm Stock Exchange

594.50SEK
23 Feb 2018
Change (% chg)

-3.50kr (-0.59%)
Prev Close
598.00kr
Open
599.00kr
Day's High
606.50kr
Day's Low
590.00kr
Volume
43,019
Avg. Vol
32,516
52-wk High
717.00kr
52-wk Low
415.50kr

Chart for

About

Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a... (more)

Overall

Beta: 0.58
Market Cap(Mil.): kr14,480.65
Shares Outstanding(Mil.): 21.71
Dividend: 2.60
Yield (%): 0.39

Financials

  Industry Sector
P/E (TTM): -- 32.19 16.60
EPS (TTM): -- -- --
ROI: -- 13.90 10.66
ROE: -- 16.72 14.30

BRIEF-Vitrolife hikes dividend, Q4 EBITDA up yr/yr

* Q4 ‍SALES AMOUNTED TO SEK 271 (251) MILLION, CORRESPONDING TO AN INCREASE OF 8 PERCENT IN SEK​

08 Feb 2018

BRIEF-Vitrolife says Embryoscope approved for sales in China

* SAYS ‍HAS TODAY RECEIVED MARKET APPROVAL FOR TIME-LAPSE INCUBATOR EMBRYOSCOPE IN CHINA​ Source text for Eikon: Further company coverage: (Stockholm Newsroom)

01 Feb 2018

BRIEF-Vitrolife buys licensing rights for embryo transfer technology

* VITROLIFE ACQUIRES LICENSING RIGHTS TO TECHNOLOGY FOR EMBRYO TRANSFER

11 Jan 2018

BRIEF-William Demant fund raises stake in Vitrolife to 21.6 pct

* William Demants Og Hustru Ida Emilies Fond​ (Oticon fund) raises stake in Vitrolife AB to 21.6 percent

10 Nov 2017

BRIEF-Vitrolife Q3 core profit rises, like-for-like sales grow 20 pct​

* Q3 ‍sales amounted to SEK 246 (210) million, corresponding to an increase of 17 percent in SEK​

02 Nov 2017

Earnings vs. Estimates